3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia
42
Leukemia, Lymphocytic, Chronic, B-Cell
41
Lymphoma
30
Myelodysplastic Syndromes
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Lymphoma, Non-Hodgkin
18
Hodgkin Disease
18
Leukemia, Myeloid, Acute
17
Multiple Myeloma
16
Myeloproliferative Disorders
14
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Neoplasms, Plasma Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Congenital Abnormalities
9
Lymphoma, T-Cell, Peripheral
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Hematologic Neoplasms
8
Burkitt Lymphoma
8
Anemia, Aplastic
8
Waldenstrom Macroglobulinemia
7
Recurrence
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Large-Cell, Immunoblastic
7
Primary Myelofibrosis
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
6
Leukemia, Myeloid, Accelerated Phase
6
Interventions
Mitomycin
3
Hyperthermic Intraperitoneal Chemotherapy
3
Surveys and Questionnaires
2
Fluorouracil
2
Capecitabine
2
tislelizumab
1
molgramostim
1
irinotecan sucrosofate
1
Tacrolimus
1
Standard of Care
1
Sirolimus
1
Referral and Consultation
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Observation
1
Methods
1
Leucovorin
1
Lansoprazole
1
Ifosfamide
1
Gemcitabine
1
Early Intervention, Educational
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Clarithromycin
1
Cisplatin
1
Carboplatin
1
Bromelains
1
Behavior Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pseudomyxoma Peritonei
×
Alemtuzumab
×
Clear all
NCT06084780
2026-04-09
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled